Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis

Conditions

• JAK2 Mutation

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ropeginterferon — DRUG
  Patients will receive Ropeginterferon

Study Details

The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm. The main questions it aims to answer are: * Can we enroll 12 patients with JAK2 mutations and high risk features without a myeloproliferative neoplasm on a clinical trial evaluating the drug ropeginterferon? * Is ropeginterferon safe to use in these patients? Participants will: * Receive ropeginterferon as an injection under the skin once every 4 weeks * Visit the clinic every 1-3 months for checkups and tests

Key Dates

First listed

Nov 25, 2025

Start date

Jul 24, 2026

Status verified

Jul 2026

Primary completion

Aug 31, 2030

Completion

Aug 31, 2030

Study Design

Enrollment

12 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Ropeginterferon

Primary Outcome Measure

Number of patients consented and enrolled within 2 years of study opening [ Time Frame: 2 years ]

Central Contacts

• Chi-Joan How
  617-732-5190
  [email protected]

Locations (1)

Find similar trials in Boston, MA